Guggenheim Initiates Coverage on GH Research (NASDAQ:GHRS)

Equities research analysts at Guggenheim started coverage on shares of GH Research (NASDAQ:GHRS) in a research note issued on Thursday, MarketBeat.com reports. The brokerage set a “buy” rating and a $32.00 price target on the stock. Guggenheim’s price target would suggest a potential upside of 190.91% from the company’s previous close.

A number of other brokerages have also recently commented on GHRS. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of GH Research in a report on Monday, January 27th. Stifel Nicolaus upped their target price on shares of GH Research from $18.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, February 27th. Canaccord Genuity Group reduced their target price on shares of GH Research from $31.00 to $28.00 and set a “buy” rating for the company in a report on Monday, November 18th. Royal Bank of Canada began coverage on shares of GH Research in a report on Friday, March 7th. They issued an “outperform” rating and a $31.00 target price for the company. Finally, Cantor Fitzgerald assumed coverage on shares of GH Research in a report on Thursday, February 13th. They issued an “overweight” rating and a $14.00 target price for the company. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $30.86.

GH Research Price Performance

NASDAQ GHRS opened at $11.00 on Thursday. GH Research has a 1 year low of $6.00 and a 1 year high of $20.50. The company has a market capitalization of $572.31 million, a PE ratio of -13.92 and a beta of 0.94. The company has a fifty day moving average of $11.13 and a two-hundred day moving average of $9.19.

GH Research (NASDAQ:GHRS) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.06. On average, research analysts expect that GH Research will post -0.8 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Woodline Partners LP raised its holdings in GH Research by 112.0% during the fourth quarter. Woodline Partners LP now owns 78,949 shares of the company’s stock worth $553,000 after purchasing an additional 41,711 shares in the last quarter. Two Sigma Investments LP purchased a new position in GH Research in the fourth quarter valued at about $117,000. Millennium Management LLC purchased a new position in GH Research in the fourth quarter valued at about $145,000. BNP Paribas Financial Markets purchased a new position in GH Research in the fourth quarter valued at about $44,000. Finally, AdvisorShares Investments LLC increased its holdings in GH Research by 15.4% in the fourth quarter. AdvisorShares Investments LLC now owns 36,011 shares of the company’s stock valued at $252,000 after buying an additional 4,806 shares in the last quarter. 56.90% of the stock is owned by hedge funds and other institutional investors.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).